Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
 
Under the partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology among others.
 
“Yale is one of the top-ranked academic institutions in the U.S. and we at Jubilant Biosys are delighted to be able to support scientific endeavors of investigators at Yale to pursue novel target ideas for unmet medical conditions,” said Marcel Velterop, president, Jubilant Biosys. “With our new discovery chemistry site scheduled to commence operations in 2021, we will further add to our capability a new infrastructure to service our partners.”
 
Bill Wiesler, director of new ventures and the Blavatnik fund for innovation at Yale’s office of cooperative research, said, “Our CRO relationships are an integral component in our pursuit of helping Yale’s scientific community transition their research towards commercialization, and we are pleased to have Jubilant Biosys join our entrepreneurial ecosystem.”